Condition: Non-Small Cell Lung Cancer · Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), a enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of antibodies to specifically target tumour cells with the highly potent killing activity of drugs with payloads too toxic for systemic administration. This is a Phase 2 study to evaluate the efficacy,and safety of TQB2102 for injection in locally advanced or metastatic non-small cell lung cancer with HER2 gene abnormality.
This description comes directly from the study's public registry record.
Li Zhang, Doctor · 020-87343458 · Zhangli6@mail.sysu.edu.cn
Qiming Wang, Doctor · 13783590691 · qimingwang1006@126.com
Always discuss trial participation with your own doctor first.
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Recruiting |
| Foshan First People's Hospital | Foshan, Guangdong, China | Not Yet Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Jiangmen Central Hospital | Jiangmen, Guangdong, China | Not Yet Recruiting |
| The Second People's Hospital of Shenzhen | Shenzhen, Guangdong, China | Not Yet Recruiting |
| Guangxi Medical University Cancer Hospital | Nanning, Guangxi, China | Not Yet Recruiting |
| The Second Affiliated Hospital of Zunyi Medical University | Zunyi, Guizhou, China | Not Yet Recruiting |
| Harbin Medical University cancer hospital | Harbin, Heilongjiang, China | Not Yet Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Not Yet Recruiting |
| Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | Not Yet Recruiting |
| Hunan Provincial Tumor Hospital | Changsha, Hunan, China | Not Yet Recruiting |
| Jiangsu Provincial People's Hospital | Nanjing, Jiangsu, China | Not Yet Recruiting |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06496490